EvidenceHealthVitaminsSupplementsMineralsCancer
Selenium, Vitamin E & Prostate Cancer (SELECT)
- Study type:
- Large randomised, double‑blind, placebo‑controlled 2×2 factorial cancer‑prevention trial
- Topic:
- Selenium and vitamin E supplementation and prostate cancer risk in healthy men
- Added:
- 2026-01-11
- Status:
- published
Strength of evidence
Very low – excellent randomisation and blinding with long follow‑up, but no true Null‑control arm and prostate cancer defined entirely via diagnostic procedures and pathology; under WorthDay's strict evidence criteria this provides only very low‑quality causal evidence, while offering a strong negative signal against benefit and a clear harm signal for vitamin E.
Source
Klein EA, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–1556.
Open original studyThe SELECT trial tested whether selenium (200 μg/day) and vitamin E (400 IU/day), alone or combined, could prevent prostate cancer in over 35,000 healthy men. Supplements were stopped early when it became clear that neither selenium nor vitamin E reduced prostate cancer. With extended follow‑up, men taking vitamin E alone had a statistically significant increase in prostate cancer risk compared with placebo. Under WorthDay's criteria, the trial is still hypothesis‑generating, but it clearly does not support vitamin E or selenium as safe prostate‑cancer‑prevention supplements.
Key findings
- 35,533 relatively healthy men (≥50/55 years) from the US, Canada and Puerto Rico were randomised to selenium (200 μg/day), vitamin E (400 IU/day), both, or placebo.
- The primary endpoint was the incidence of pathologically confirmed prostate cancer, detected through PSA testing, digital rectal examination and biopsy.
- Initial analyses showed no protective effect of selenium or vitamin E; the trial supplements were discontinued early due to lack of benefit.
- With extended follow‑up, the vitamin‑E‑only group had a significantly higher prostate cancer incidence than placebo (about 620 vs 529 cases; HR ≈ 1.17 with a high‑confidence interval just above 1.0).
- Selenium alone or in combination with vitamin E did not produce a significant increase or decrease in prostate cancer risk, and there was no clear benefit for overall cancer or mortality.
- Under WorthDay's criteria, diagnostically defined cancer endpoints and the absence of a true Null‑control arm limit causal certainty, but the data strongly argue against using vitamin E or selenium supplements to prevent prostate cancer and highlight a potential harm signal for vitamin E.
Background
- Selenium and vitamin E were widely promoted as possible "natural" protectors against cancer, including prostate cancer. Observational studies and smaller trials had suggested that higher selenium status or vitamin E intake might be linked to lower prostate cancer incidence. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was designed as a definitive, large‑scale, randomised trial to test whether daily selenium and/or vitamin E supplements reduce prostate cancer risk in otherwise healthy men.
Methods
- Species / population: 35,533 relatively healthy men recruited from 427 study sites in the United States, Canada and Puerto Rico. Key eligibility criteria included: No prior prostate cancer diagnosis. Prostate‑specific antigen (PSA) ≤ 4.0 ng/mL. Normal or non‑suspicious digital rectal examination. Age ≥ 50 years for black men and ≥ 55 years for all others. Design: Randomised, double‑blind, placebo‑controlled 2×2 factorial trial. Interventions: Selenium group: 200 μg/day L‑selenomethionine plus placebo vitamin E. Vitamin E group: 400 IU/day all rac‑α‑tocopheryl acetate plus placebo selenium. Combination group: both selenium and vitamin E at the above doses. Placebo group: matching placebos for both agents. Follow‑up: Men were randomised between 2001 and 2004, with planned follow‑up of 7–12 years. Supplementation was stopped early when interim analyses showed no evidence of benefit, but follow‑up for outcomes continued. The 2011 JAMA report includes additional person‑years and prostate cancer cases beyond the initial publication. Endpoints (as defined by the investigators): Primary endpoint: incidence of prostate cancer, based on clinical detection (PSA screening, digital rectal exam) and pathological confirmation by biopsy. Secondary endpoints: incidence of other cancers, overall cancer incidence, and mortality. Cancer outcomes were thus defined via diagnostic protocols and pathology, not via simple direct mechanical observation.
Results
- The extended analysis reported: Placebo group: 529 prostate cancer cases. Vitamin E group: 620 prostate cancer cases. Corresponding hazard ratio (HR) ≈ 1.17, with a 99 % confidence interval slightly above 1.0, indicating a statistically significant increase in risk compared with placebo. Selenium group: 575 prostate cancer cases. HR ≈ 1.09; confidence interval included 1.0 -> no statistically significant difference vs placebo. Selenium + vitamin E group: 555 prostate cancer cases. HR ≈ 1.05; confidence interval also included 1.0 -> no significant effect. In absolute terms, the vitamin‑E‑only arm showed about 1.6 extra prostate cancer cases per 1,000 person‑years compared with placebo; selenium alone and the combination had smaller, non‑significant absolute differences. There was no convincing evidence that selenium, vitamin E, or their combination reduced overall cancer incidence or overall mortality.
Interpretation
- For WorthDay, S0034 is an important cautionary example: A large, well‑run, double‑blind prevention trial in more than 35,000 healthy men failed to show any protective effect of selenium or vitamin E supplements against prostate cancer. Instead, vitamin E alone was associated with a statistically significant increase in prostate cancer risk over long‑term follow‑up. This contradicts the popular narrative that these supplements are harmless or protective against prostate cancer. Rather than acting as "nutritional insurance," vitamin E supplementation in this context appears to tilt risk in the wrong direction. Under WorthDay's strict evidence criteria, several methodological points limit how far causal claims can be taken: No true Null‑control arm: All participants ingested capsules (active or placebo). From a WorthDay viewpoint, this means potential generic capsule‑ or expectation‑related effects cannot be entirely separated from specific vitamin effects. Diagnostic endpoints: Prostate cancer is detected through PSA testing, rectal examination, imaging and biopsy, and then defined via histopathology. These layered diagnostic procedures make the endpoint "soft" once it is used for causal claims about supplementation, because they embed assumptions and classification rules. Relative rather than absolute emphasis: The main results are reported as hazard ratios. The absolute differences in risk, although statistically significant for vitamin E, remain modest; assessing clinical relevance requires focusing on these absolute risk increases. Nonetheless, taken together, the data provide a robust negative signal: There is no evidence that selenium or vitamin E supplements meaningfully lower prostate cancer risk in this setting. There is a clear signal that vitamin E supplementation, at the tested dose and duration, increases the incidence of prostate cancer.
Limitations
- Population specifics: The trial focused on relatively healthy, mostly North American men meeting specific PSA and age criteria; results may not generalise perfectly to all populations or to men with markedly different diets or baseline selenium/vitamin E status.
- No targeted deficiency: SELECT did not select for men with documented selenium or vitamin E deficiency; effects in truly deficient individuals remain unclear.
- Diagnostic dependency: Outcomes depend on PSA screening patterns and biopsy practices, which can influence detection rates and may change over time.
- Lack of Null‑control: There is no group without any capsule intake, so capsule‑related behaviours or expectations remain a theoretical confound under WorthDay's logic.
WorthDay perspective
- S0034 illustrates that cancer‑prevention supplement strategies can backfire: a widely promoted antioxidant vitamin increased the risk of the very cancer it was supposed to prevent.
- For WorthDay, this argues strongly against recommending selenium or vitamin E supplements as a generic prostate‑cancer‑prevention measure in healthy men.
- The study reinforces the platform's focus on whole‑food nutrition, lifestyle and environmental factors, rather than relying on isolated high‑dose supplements for cancer prevention.
Permalink: https://www.worth-day.com/science-compass/s0034-selenium-vitamin-e-prostate-cancer-select
Related studies
Science meets practice